Delcath Systems : Melphalan/HDS Study Outcomes To Be Published

(RTTNews) - Delcath Systems Inc. (DCTH) said that a review of clinical research treatment outcomes using Melphalan Hydrochloride for Injection with the Delcath Hepatic Delivery System (Melphalan/HDS) in patients with hepatic metastases has been accepted for publication in the prestigious journal, Cancer Control.

"We are especially pleased to have these data accepted for publication as they underscore the positive outcomes for patients with hepatic metastases treated with Melphalan/HDS, and represent another example of the high quality research being conducted with our therapy in both the United States and Europe," stated Jennifer K. Simpson, Ph.D., MSN, CRNP, President and CEO of Delcath Systems.